Literature DB >> 28113195

On Quantitative Biomarkers of VNS Therapy Using EEG and ECG Signals.

Maryam Ravan, Shivkumar Sabesan, O'Neill D'Cruz.   

Abstract

OBJECTIVE: The goal of this work is to objectively evaluate the effectiveness of neuromodulation therapies, specifically, Vagus nerve stimulation (VNS) in reducing the severity of seizures in patients with medically refractory epilepsy.
METHODS: Using novel quantitative features obtained from combination of electroencephalographic (EEG) and electrocardiographic (ECG) signals around seizure events in 16 patients who underwent implantation of closed-loop VNS therapy system, namely AspireSR, we evaluated if automated delivery of VNS at the time of seizure onset reduces the severity of seizures by reducing EEG spatial synchronization as well as the duration and magnitude of heart rate increase. Unsupervised classification was subsequently applied to test the discriminative ability and validity of these features to measure responsiveness to VNS therapy.
RESULTS: Results of application of this methodology to compare 105 pre-VNS treatment and 107 post-VNS treatment seizures revealed that seizures that were acutely stimulated using VNS had a reduced ictal spread as well as reduced impact on cardiovascular function compared to the ones that occurred prior to any treatment. Furthermore, application of an unsupervised fuzzy-c-mean classifier to evaluate the ability of the combined EEG-ECG based features to classify pre and post-treatment seizures achieved a classification accuracy of 85.85%.
CONCLUSION: These results indicate the importance of timely delivery of VNS to reduce seizure severity and thus help achieve better seizure control for patients with epilepsy. SIGNIFICANCE: The proposed set of quantitative features could be used as potential biomarkers for predicting long-term response to VNS therapy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28113195     DOI: 10.1109/TBME.2016.2554559

Source DB:  PubMed          Journal:  IEEE Trans Biomed Eng        ISSN: 0018-9294            Impact factor:   4.538


  4 in total

1.  Cortical Responses to Vagus Nerve Stimulation Are Modulated by Brain State in Nonhuman Primates.

Authors:  Irene Rembado; Weiguo Song; David K Su; Ariel Levari; Larry E Shupe; Steve Perlmutter; Eberhard Fetz; Stavros Zanos
Journal:  Cereb Cortex       Date:  2021-10-22       Impact factor: 4.861

Review 2.  Current Directions in the Auricular Vagus Nerve Stimulation II - An Engineering Perspective.

Authors:  Eugenijus Kaniusas; Stefan Kampusch; Marc Tittgemeyer; Fivos Panetsos; Raquel Fernandez Gines; Michele Papa; Attila Kiss; Bruno Podesser; Antonino Mario Cassara; Emmeric Tanghe; Amine Mohammed Samoudi; Thomas Tarnaud; Wout Joseph; Vaidotas Marozas; Arunas Lukosevicius; Niko Ištuk; Sarah Lechner; Wlodzimierz Klonowski; Giedrius Varoneckas; Jozsef Constantin Széles; Antonio Šarolić
Journal:  Front Neurosci       Date:  2019-07-24       Impact factor: 4.677

3.  Vagus nerve stimulation therapy in people with drug-resistant epilepsy (CORE-VNS): rationale and design of a real-world post-market comprehensive outcomes registry.

Authors:  Arjune Sen; Ryan Verner; James P Valeriano; Ricky Lee; Muhammad Zafar; Rhys Thomas; Katarzyna Kotulska; Ellen Jespers; Maxine Dibué; Patrick Kwan
Journal:  BMJ Neurol Open       Date:  2021-12-23

Review 4.  Evolution of the Vagus Nerve Stimulation (VNS) Therapy System Technology for Drug-Resistant Epilepsy.

Authors:  Pegah Afra; Bola Adamolekun; Seyhmus Aydemir; Glenn David Robert Watson
Journal:  Front Med Technol       Date:  2021-08-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.